|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
MAY POTENTIATE THE ACTION OF DIAZEPAM
|
MAY POTENTIATE THE ACTION OF DIAZEPAM
|
MAY POTENTIATE THE ACTION OF DIAZEPAM
|
MAY POTENTIATE THE ACTION OF DIAZEPAM
|
MAY POTENTIATE THE ACTION OF DIAZEPAM
|
MAY POTENTIATE THE ACTION OF DIAZEPAM
|
MAY POTENTIATE THE ACTION OF DIAZEPAM
|
MAY POTENTIATE THE ACTION OF DIAZEPAM
|
MAY POTENTIATE THE ACTION OF DIAZEPAM
|
MAY POTENTIATE THE ACTION OF DIAZEPAM
|
MAY POTENTIATE THE ACTION OF DIAZEPAM
|
MAY POTENTIATE THE ACTION OF DIAZEPAM
|
MAY POTENTIATE THE ACTION OF DIAZEPAM
|
MAY POTENTIATE THE ACTION OF DIAZEPAM
|
MAY POTENTIATE THE ACTION OF DIAZEPAM
|
MAY POTENTIATE THE ACTION OF DIAZEPAM
|
PROPOXYPHENE & DEXTROPROPOXYPHENE INHIBIT LIVER METABOLISM OF BENZODIAZEPINES, BETABLOCKERS, CARBAMAZEPINE, PHENYTOIN & WARFARIN, SO REDUCE THEIR DOSE BY 1/3
|
PROPOXYPHENE & DEXTROPROPOXYPHENE INHIBIT LIVER METABOLISM OF BENZODIAZEPINES, BETABLOCKERS, CARBAMAZEPINE, PHENYTOIN & WARFARIN, SO REDUCE THEIR DOSE BY 1/3
|
PROPOXYPHENE & DEXTROPROPOXYPHENE INHIBIT LIVER METABOLISM OF BENZODIAZEPINES, BETABLOCKERS, CARBAMAZEPINE, PHENYTOIN & WARFARIN, SO REDUCE THEIR DOSE BY 1/3
|
PROPOXYPHENE & DEXTROPROPOXYPHENE INHIBIT LIVER METABOLISM OF BENZODIAZEPINES, BETABLOCKERS, CARBAMAZEPINE, PHENYTOIN & WARFARIN, SO REDUCE THEIR DOSE BY 1/3
|
PROPOXYPHENE & DEXTROPROPOXYPHENE INHIBIT LIVER METABOLISM OF BENZODIAZEPINES, BETABLOCKERS, CARBAMAZEPINE, PHENYTOIN & WARFARIN, SO REDUCE THEIR DOSE BY 1/3
|
PROPOXYPHENE & DEXTROPROPOXYPHENE INHIBIT LIVER METABOLISM OF BENZODIAZEPINES, BETABLOCKERS, CARBAMAZEPINE, PHENYTOIN & WARFARIN, SO REDUCE THEIR DOSE BY 1/3
|
PROPOXYPHENE & DEXTROPROPOXYPHENE INHIBIT LIVER METABOLISM OF BENZODIAZEPINES, BETABLOCKERS, CARBAMAZEPINE, PHENYTOIN & WARFARIN, SO REDUCE THEIR DOSE BY 1/3
|
PROPOXYPHENE & DEXTROPROPOXYPHENE INHIBIT LIVER METABOLISM OF BENZODIAZEPINES, BETABLOCKERS, CARBAMAZEPINE, PHENYTOIN & WARFARIN, SO REDUCE THEIR DOSE BY 1/3
|
PROPOXYPHENE & DEXTROPROPOXYPHENE INHIBIT LIVER METABOLISM OF BENZODIAZEPINES, BETABLOCKERS, CARBAMAZEPINE, PHENYTOIN & WARFARIN, SO REDUCE THEIR DOSE BY 1/3
|
PROPOXYPHENE & DEXTROPROPOXYPHENE INHIBIT LIVER METABOLISM OF BENZODIAZEPINES, BETABLOCKERS, CARBAMAZEPINE, PHENYTOIN & WARFARIN, SO REDUCE THEIR DOSE BY 1/3
|
PROPOXYPHENE & DEXTROPROPOXYPHENE INHIBIT LIVER METABOLISM OF BENZODIAZEPINES, BETABLOCKERS, CARBAMAZEPINE, PHENYTOIN & WARFARIN, SO REDUCE THEIR DOSE BY 1/3
|
PROPOXYPHENE & DEXTROPROPOXYPHENE INHIBIT LIVER METABOLISM OF BENZODIAZEPINES, BETABLOCKERS, CARBAMAZEPINE, PHENYTOIN & WARFARIN, SO REDUCE THEIR DOSE BY 1/3
|
PROPOXYPHENE & DEXTROPROPOXYPHENE INHIBIT LIVER METABOLISM OF BENZODIAZEPINES, BETABLOCKERS, CARBAMAZEPINE, PHENYTOIN & WARFARIN, SO REDUCE THEIR DOSE BY 1/3
|
PROPOXYPHENE & DEXTROPROPOXYPHENE INHIBIT LIVER METABOLISM OF BENZODIAZEPINES, BETABLOCKERS, CARBAMAZEPINE, PHENYTOIN & WARFARIN, SO REDUCE THEIR DOSE BY 1/3
|
PROPOXYPHENE & DEXTROPROPOXYPHENE INHIBIT LIVER METABOLISM OF BENZODIAZEPINES, BETABLOCKERS, CARBAMAZEPINE, PHENYTOIN & WARFARIN, SO REDUCE THEIR DOSE BY 1/3
|
PROPOXYPHENE & DEXTROPROPOXYPHENE INHIBIT LIVER METABOLISM OF BENZODIAZEPINES, BETABLOCKERS, CARBAMAZEPINE, PHENYTOIN & WARFARIN, SO REDUCE THEIR DOSE BY 1/3
|
PROPOXYPHENE & DEXTROPROPOXYPHENE INHIBIT LIVER METABOLISM OF BENZODIAZEPINES, BETABLOCKERS, CARBAMAZEPINE, PHENYTOIN & WARFARIN, SO REDUCE THEIR DOSE BY 1/3
|
PROPOXYPHENE & DEXTROPROPOXYPHENE INHIBIT LIVER METABOLISM OF BENZODIAZEPINES, BETABLOCKERS, CARBAMAZEPINE, PHENYTOIN & WARFARIN, SO REDUCE THEIR DOSE BY 1/3
|
PROPOXYPHENE & DEXTROPROPOXYPHENE INHIBIT LIVER METABOLISM OF BENZODIAZEPINES, BETABLOCKERS, CARBAMAZEPINE, PHENYTOIN & WARFARIN, SO REDUCE THEIR DOSE BY 1/3
|
PROPOXYPHENE & DEXTROPROPOXYPHENE INHIBIT LIVER METABOLISM OF BENZODIAZEPINES, BETABLOCKERS, CARBAMAZEPINE, PHENYTOIN & WARFARIN, SO REDUCE THEIR DOSE BY 1/3
|
PROPOXYPHENE & DEXTROPROPOXYPHENE INHIBIT LIVER METABOLISM OF BENZODIAZEPINES, BETABLOCKERS, CARBAMAZEPINE, PHENYTOIN & WARFARIN, SO REDUCE THEIR DOSE BY 1/3
|
PROPOXYPHENE & DEXTROPROPOXYPHENE INHIBIT LIVER METABOLISM OF BENZODIAZEPINES, BETABLOCKERS, CARBAMAZEPINE, PHENYTOIN & WARFARIN, SO REDUCE THEIR DOSE BY 1/3
|
PROPOXYPHENE & DEXTROPROPOXYPHENE INHIBIT LIVER METABOLISM OF BENZODIAZEPINES, BETABLOCKERS, CARBAMAZEPINE, PHENYTOIN & WARFARIN, SO REDUCE THEIR DOSE BY 1/3
|
PROPOXYPHENE & DEXTROPROPOXYPHENE INHIBIT LIVER METABOLISM OF BENZODIAZEPINES, BETABLOCKERS, CARBAMAZEPINE, PHENYTOIN & WARFARIN, SO REDUCE THEIR DOSE BY 1/3
|
PROPOXYPHENE & DEXTROPROPOXYPHENE INHIBIT LIVER METABOLISM OF BENZODIAZEPINES, BETABLOCKERS, CARBAMAZEPINE, PHENYTOIN & WARFARIN, SO REDUCE THEIR DOSE BY 1/3
|
PROPOXYPHENE & DEXTROPROPOXYPHENE INHIBIT LIVER METABOLISM OF BENZODIAZEPINES, BETABLOCKERS, CARBAMAZEPINE, PHENYTOIN & WARFARIN, SO REDUCE THEIR DOSE BY 1/3
|
PROPOXYPHENE & DEXTROPROPOXYPHENE INHIBIT LIVER METABOLISM OF BENZODIAZEPINES, BETABLOCKERS, CARBAMAZEPINE, PHENYTOIN & WARFARIN, SO REDUCE THEIR DOSE BY 1/3
|
PROPOXYPHENE & DEXTROPROPOXYPHENE INHIBIT LIVER METABOLISM OF BENZODIAZEPINES, BETABLOCKERS, CARBAMAZEPINE, PHENYTOIN & WARFARIN, SO REDUCE THEIR DOSE BY 1/3
|
PROPOXYPHENE & DEXTROPROPOXYPHENE INHIBIT LIVER METABOLISM OF BENZODIAZEPINES, BETABLOCKERS, CARBAMAZEPINE, PHENYTOIN & WARFARIN, SO REDUCE THEIR DOSE BY 1/3
|
MAY INCREASE DROWSINESS EFFECT
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
ORTHOSTATIC HYPOTENSION IS AGGRAVATED
|
ORTHOSTATIC HYPOTENSION IS AGGRAVATED
|
ORTHOSTATIC HYPOTENSION IS AGGRAVATED
|
ORTHOSTATIC HYPOTENSION IS AGGRAVATED
|
AMPHETAMINE CNS STIMULATION IS POTENTIATED & FATAL CONVULSIONS CAN OCCUR IN CASES OF PROPOXYPHENE OVERDOSE
|
AMPHETAMINE CNS STIMULATION IS POTENTIATED & FATAL CONVULSIONS CAN OCCUR IN CASES OF PROPOXYPHENE OVERDOSE
|
AMPHETAMINE CNS STIMULATION IS POTENTIATED & FATAL CONVULSIONS CAN OCCUR IN CASES OF PROPOXYPHENE OVERDOSE
|
AMPHETAMINE CNS STIMULATION IS POTENTIATED & FATAL CONVULSIONS CAN OCCUR IN CASES OF PROPOXYPHENE OVERDOSE
|
AMPHETAMINE CNS STIMULATION IS POTENTIATED & FATAL CONVULSIONS CAN OCCUR IN CASES OF PROPOXYPHENE OVERDOSE
|